Synaptogenix Inc (SNPX)

[InTheTrenches]

Another failed Alzheimer's trial:

http://finance.yahoo.com/news/acceras-alzheimers-trial-fails-yet-133000260.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANjNGphaDlwY2JhdnMwBGcDZFhWcFpEeHVjejVsTkdOak5UUXpNeTAyWWpreUxUTXdNREV0T0RReU15MHpaakUzTUdKak5EWXpNelE4Wm1sbGJHUStiWEpyBGxhbmcDZW4tVVMEb3JpZ19sYW5nA2VuBG9yaWdfcmVnaW9uA1VTBHBvcwMwBHJlZ2lvbgNVUwRzeW1ib2wDTVJL?.tsrc=applewf

Nestle SA-backed Accera, late-stage study, in mild-to-moderate AD, failed to achieve statistically significant result.

1204 drug is based on the theory that decreasing ability to metabolize glucose leads to deposition of amyloid.

After successful mid-stage trial, Accera changed 1204's formulation, but that led to lower bioavailability of the drug. They have fixed the formulation and will start another late-stage study.

"Industry analysts say any treatment that successfully interferes with the cause of the disease would be virtually guaranteed multi-billion dollars in sales."